// App-Quantinova.ai

1965 : Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Researchers

Presenter

  • Todd E. DeFor

Principal Investigators

  • David H. Vesole

  • Christopher Bredeson

  • Linda J Burns

Medical Centers

  • Division of Endocrinology, The Ottawa Hospital, Ottawa, ON, Canada

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Avascular necrosis

  • Renal insufficiency

  • Osteoporosis

  • Osteopenia

  • Multiple Myeloma

Biomarkers

  • N-terminal telopeptide

  • Paired box 5

  • Bone Mineral Density

Drug/Treatment

  • Zolendronic acid

  • Ergocalciferol

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved